PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
13 Mai 2021 - 3:30PM
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a
highly differentiated, multi-product, commercial-stage medical
technology company, and its major subsidiary Lucid Diagnostics Inc.
(“Lucid”), announced today that David Poppers, M.D. Ph.D. will be
presenting data on his team’s initial experience using Lucid’s
EsoCheck® Esophageal Cell Collection Device and EsoGuard®
Esophageal DNA Test at the upcoming Digestive Disease Week
2021 medical conference, which will be held virtually May
21-23, 2021.
Dr. Poppers is Clinical Professor, Division of
Gastroenterology and Hepatology at NYU Langone Medical Center in
New York City, and an expert in advanced endoscopy and esophageal
disease. His presentation, entitled EsoCheck/EsoGuard: a Novel,
Simple, Outpatient Technology for the Early Detection of Esophageal
Intestinal Metaplasia, Dysplasia, and Adenocarcinoma, will be
presented during poster session 7110 to be held on Sunday, May 23,
2021 between 12:15 PM and 1 PM EDT.
Digestive Disease Week® (DDW) is the largest
international gathering of physicians, researchers, and academics
in the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery. DDW is jointly sponsored by the American
Association for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA) Institute, the American
Society for Gastrointestinal Endoscopy (ASGE) and the Society for
Surgery of the Alimentary Tract (SSAT).
About PAVmed and LucidPAVmed
Inc. is a highly differentiated, multi-product, commercial-stage
medical technology company with a diversified product pipeline
addressing unmet clinical needs encompassing a broad spectrum of
clinical areas with attractive regulatory pathways and market
opportunities. Its major subsidiary, Lucid Diagnostics Inc.,
markets the first and only commercial tools for widespread early
detection of esophageal precancer and cancer – the EsoGuard®
Esophageal DNA Test and EsoCheck® Esophageal Cell Collection
Device. Its GI Health division also includes the complementary
EsoCure™ Esophageal Ablation Device with Caldus™ Technology. Its
Minimally Invasive Interventions markets its CarpX® Minimally
Invasive Device for Carpal Tunnel Syndrome. Other divisions include
Infusion Therapy (PortIO™ Implantable Intraosseus Vascular Access
Device and NextFlo™ Intravenous Infusion Set), and Emerging
Innovations (non-invasive laser-based glucose monitoring, pediatric
ear tubes, and mechanical circulatory support). For more
information, please visit www.pavmed.com, follow us on
Twitter, connect with us on LinkedIn, and watch our videos on
YouTube. For more information on our majority owned subsidiary,
Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid
on Twitter, and connect with Lucid on LinkedIn. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements, based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, our ability to
complete our strategic initiatives, volatility in the price of
PAVmed’s common stock, Series W Warrants and Series Z Warrants;
general economic and market conditions; the uncertainties inherent
in research and development, including the cost and time required
advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; the
effectiveness of our marketing initiatives; the establishment of
government and private payment insurance coverage; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market many of its products. The Company
has been monitoring the COVID-19 pandemic and its impact on our
business. The Company expects the significance of the COVID-19
pandemic, including the extent of its effect on the Company’s
financial and operational results, to be dictated by, among other
things, the success of efforts to contain it and the impact of
actions taken in response. New risks and uncertainties may arise
from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s future operations, see Part I, Item IA,
“Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed after its most recent Annual
Report. PAVmed disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
Contacts:
InvestorsMike HavrillaDirector of Investor
Relations(814) 241-4138JMH@PAVmed.com
MediaShaun O’NeilChief Commercial Officer(518)
812-3087SMO@PAVmed.com
Jim Heins / Katie GallagherLaVoieHealthScience(646) 491-7042 /
(617) 792-3937PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Apr 2023 bis Apr 2024